BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Oprah Winfrey's Favorite Wellness Destination Is A Luxurious Italian Retreat - 2Architect Frank Gehry has died: See his most iconic buildings
- 3Popular Film Areas: A Worldwide Manual for Film Enchantment
- 4The 10 Most Noteworthy Games in History
- 5Congo declares its latest Ebola outbreak over, after 43 deaths
- Egypt's cafés and shops forced to close early due to Iran war
- Pick Your Top Method for starting the Morning
- New portrait of the oldest-known supernova | Space photo of the day for March 27, 2026
- Check out the exclusive pitch deck Valerie Health used to raise $30 million from Redpoint Ventures to automate healthcare faxes
- Saudi Arabia says it intercepted 7 missiles, debris falls near energy facilities
- Politics at the table? Drinking the wine you brought? An etiquette expert's Thanksgiving dos and don'ts.
- A 'rampaging lion' nebula roars to life in a stunning deep-space photo
- Colleges say foreign students feel 'unwelcome' in the U.S. amid big drop in international enrollment, new survey finds
- Nick Reiner's defense attorney asks to be replaced, again delaying arraignment in connection with the stabbing deaths of his parents, Rob Reiner and Michele Singer Reiner
